Mortality In Patients With Respiratory And Nonrespiratory Carbapenem Resistant-Multidrug Resistant Acinetobacter Infections.

BACKGROUND Mortality from carbapenem-multi-drug resistant Acinetobacter infections may vary according to site of infection. The objective of this study was to compare mortality in respiratory vs. non-respiratory infection with Carbapenem-Multi-drug Resistant Acinetobacter (C-MRAB). METHODS We conducted a prospective cohort study to compare mortality rate in patients with respiratory vs. nonrespiratory infection (n=30 each). RESULTS Results showed that mortality was 40% in the respiratory group compared to 23% in non-respiratory group; the difference was not statistically significant (p=0.165, RR=1.71, CI=0.73-3.75). There was a significantly higher prior admission rate in patients with respiratory infection (p=0.028). Logistic regression did not reveal any modifier effect from other variables. CONCLUSIONS This study showed no significant difference in mortality in patients with carbapenem-multi-drug resistant acinetobacter respiratory vs. non-respiratory infections.

[1]  Ratender K. Singh,et al.  Carbapenem-resistant Acinetobacter ventilator-associated pneumonia: Clinical characteristics and outcome , 2013, Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine.

[2]  Vishal Shete,et al.  Multi-drug resistant Acinetobacter ventilator-associated pneumonia , 2010, Lung India : official organ of Indian Chest Society.

[3]  M. Falagas,et al.  Treatment of Acinetobacter infections , 2010 .

[4]  A. Idil,et al.  Impact of early appropriate antimicrobial therapy on survival in Acinetobacter baumannii bloodstream infections. , 2009, International journal of antimicrobial agents.

[5]  B. Sumerkan,et al.  Factors influencing survival in patients with multi-drug-resistant Acinetobacter bacteraemia. , 2009, European journal of internal medicine.

[6]  R. Hasan,et al.  Infection control education: impact on ventilator-associated pneumonia rates in a public sector intensive care unit in Pakistan. , 2009, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[7]  A. Charlett,et al.  Antimicrobial treatment and clinical outcome for infections with carbapenem- and multiply-resistant Acinetobacter baumannii around London. , 2008, International journal of antimicrobial agents.

[8]  Harald Seifert,et al.  Acinetobacter baumannii: Emergence of a Successful Pathogen , 2008, Clinical Microbiology Reviews.

[9]  S. Cosgrove,et al.  Multidrug-resistant Acinetobacter Infection Mortality Rate and Length of Hospitalization , 2007, Emerging infectious diseases.

[10]  M. Kaufmann,et al.  Occurrence of Carbapenem-Resistant Acinetobacter baumannii Clones at Multiple Hospitals in London and Southeast England , 2006, Journal of Clinical Microbiology.

[11]  Hsin-Pai Chen,et al.  Predictors of mortality in Acinetobacter baumannii bacteremia. , 2005, Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi.

[12]  Tae Hyong Kim,et al.  Risk Factors for Acquisition of Imipenem-Resistant Acinetobacter baumannii: a Case-Control Study , 2004, Antimicrobial Agents and Chemotherapy.

[13]  P. Hsueh,et al.  Pandrug-Resistant Acinetobacter baumannii Causing Nosocomial Infections in a University Hospital, Taiwan , 2002, Emerging infectious diseases.

[14]  H. Seifert,et al.  Nosocomial Bacteremia due to Acinetobacter baumannii: Clinical Features, Epidemiology, and Predictors of Mortality , 1995, Medicine.

[15]  M. Safar,et al.  Nosocomial acquisition of multiresistant Acinetobacter baumannii: risk factors and prognosis. , 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[16]  B. Hasan,et al.  Emergence of carbapenem-resistant Acinetobacter baumannii in hospitals in Pakistan. , 2014, Journal of medical microbiology.

[17]  R. Weinstein,et al.  Acinetobacter infection. , 2008, The New England journal of medicine.